GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces its FINANCIAL communication agenda for 2015. This calendar of publication dates is for reference only; it is subject to change if necessary. Each publication will be released after Euronext market closing.
|27 January 2015||Business & Cash Position Update 4th Quarter 2014|
|2 March 2015||2014 Annual Results|
|28 April 2015||Business & Cash Position Update 1st Quarter 2015|
|11 June 2015||Annual Shareholders Meeting|
|28 July 2015||Business & Cash Position Update 2nd Quarter 2015|
|21 September 2015||2015 Half-Year Results|
|28 October 2015||Business & Cash Position Update 3rd Quarter 2015|
Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.
Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase II clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18.
Genticel is based in Paris and Toulouse and was awarded the Deloitte Technology Fast 50 “Prix Biotech d'Avenir” (Most promising Biotech) in 2014.
Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels. For more information, please visit www.genticel.com
Chief Executive Officer
USA INVESTOR CONTACT
Tel.: +1 (212) 915 2577
Tel.: +33 (0)1 53 67 36 77
Tel.: +33 (0)1 53 67 36 90